Fortitude Family Office, LLC
Family OfficePosition in QNCX — Quince Therapeutics, Inc.
CIK 1950506
SCOTTSDALE, AZ
Position in QNCX
as of Mar 31, 2026
· filed Apr 16, 2026
Position Value
$163,519
New position
Shares Held
8,095
first reported quarter
Ownership
0.050%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#29
of 46 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Fortitude Family Office, LLC holds $623,443 across 123 Biotechnology names. QNCX ranks #2 (26.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
522 | $172,714 | |
| 2 | QNCX |
Quince Therapeutics, Inc.
This page
|
8,095 | $163,519 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
75 | $33,490 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
296 | $28,786 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
25 | $19,316 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
60 | $11,343 | |
| 7 | CMPX |
Compass Therapeutics, Inc.
|
1,915 | $10,130 | |
| 8 | TERN |
Terns Pharmaceuticals, Inc.
|
192 | $10,122 |
All Filings in QNCX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $163,519 | 8,095 | Shares | Sole | 2026-04-16 | |
| No filing history on record for this holder in this stock. | ||||||